AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04859517
Drug: ADG20
RxNorm normalized name: Adintrevimab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ADG20
Trial: NCT06520163
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 6: 6mg
Trial: NCT06297668
Drug: Treatment B: BGF MDI HFO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 4 inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer.
Trial: NCT06297668
Drug: Treatment C: BGF MDI HFO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 4 inhalations of BGF MDI HFO as a single dose without spacer.
Trial: NCT05997641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually matching 0 mg DF-003 capsules.
Trial: NCT04697485
Drug: Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~* Loop diuretic (bumetanide 0.5 mg)~* Mineralocorticoid receptor antagonist (eplerenone 25 mg)~* Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg
Trial: NCT06210984
Drug: Low caffeine dose
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg/kg dose of caffeine in pill form
Trial: NCT06210984
Drug: Moderate caffeine dose
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/kg dose of caffeine in pill form
Trial: NCT06210984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg dose of maltodextrin in pill form
Trial: NCT00299208
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04353180
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment
RxNorm normalized name: isotretinoin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After three days of randomization and standard treatment , 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days.+standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Trial: NCT04353180
Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: After three days of randomization and standard treatment , Aerosolized 13 cis retinoic acid in gradual two doses increase froms 0.2 mg/kg/day to 4 mg/kg/day as inhaled 13 cis retinoic acid therapy for 14 days +standard treatment~Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Trial: NCT04353180
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Trial: NCT06447740
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
Trial: NCT05170243
Drug: 9MW1911 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenously on day 1
Trial: NCT05170243
Drug: 9MW1911 Injection Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching placebo intravenously on day 1
Trial: NCT04607200
Drug: AGEN2034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 Monoclonal Antibody
Trial: NCT04607200
Drug: AGEN1884
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CTLA-4 Monoclonal Antibody
Trial: NCT05389722
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06654960
Drug: HRS9531 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9531 injection single dose.
Trial: NCT06539013
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil infusion
Trial: NCT06539013
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use of Fentanylfor analgesia
Trial: NCT06394973
Drug: T4090 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).
Trial: NCT06187376
Drug: Chinese Herbal Medicine (CHM) supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dropper of tincture by mouth for 12 weeks.
Trial: NCT06187376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tincture.
Trial: NCT04260217
Drug: APG2575 400 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG2575 400 mg
Trial: NCT04260217
Drug: APG2575 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG2575 600 mg
Trial: NCT04260217
Drug: APG2575 800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG2575 800 mg
Trial: NCT06654596
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in glucocorticoid group will be treated with ACEI/ARB and glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d). After 8 weeks, reduce the dosage by 5 mg per month for a total of 28-40 weeks.
Trial: NCT06096597
Drug: Clarix Flo
RxNorm normalized name: Aller-Flo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride
Trial: NCT06096597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.9% preservative-free sodium chloride
Trial: NCT05667714
Drug: SA58 Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
Trial: NCT05667714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided by Sinovac Life Sciences Co. , Ltd.
Trial: NCT05913414
Drug: Polysaccharide Iron Complex Pill
RxNorm normalized name: polysaccharide iron complex Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Polysaccharide Iron Complex Pill after IC and CCRT
Trial: NCT03948022
Drug: Crinone 8% Vaginal Gel
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg daily vaginal gels
Trial: NCT05748990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.
Trial: NCT06198673
Drug: Antiplatelet Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents more commonly used at time of percutaneous coronary intervention in patients with chronic coronary syndrome
Trial: NCT05800249
Drug: PE0116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor
Trial: NCT05819918
Drug: Best available therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.
Trial: NCT05875506
Drug: doxycycline hyclate saturated chitosan dressing
RxNorm normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline hyclate ( Atridox 10% Tolmar Inc, USA) saturated chitosan dressing (HHD) HemCon dental dressing Pro ( Tricol Biomedical, Inc. USA) applied in dry socket
Trial: NCT04730648
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For newly diagnosed ACS patients with diabetes, multivessel occlusion, or recurrent ACS attack, who are willing to accept PCSK9 inhibitor injection.
Trial: NCT05268926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05279846
Drug: MOB015B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically for 48 weeks
Trial: NCT06191094
Drug: sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized 2:1 to receive either faricimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection
Trial: NCT04417894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for SC injection administration
Trial: NCT06560294
Drug: Micronized purified flavonoid fraction (Daflon ®)
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive micronized purified flavonoid fraction (Daflon ®), 500 mg twice/daily for 3 months.
Trial: NCT04630834
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive both ibuprofen 10mg/kg weight based dosing with a max of 600mg
Trial: NCT04630834
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive acetaminophen 15 mg/kg weight based dosing with a max of 650mg
Trial: NCT04630834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive placebo 15mg/kg weight based dosing with a max of 650mg
Trial: NCT04830462
Drug: Rifampicin 300 Mg Oral Capsule
RxNorm normalized name: Rifampicin 300 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg orally once daily for 4 months
Trial: NCT06146374
Drug: SLV213
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
Trial: NCT06409377
Drug: Precedex 200 MCG in 2 ML Injection
RxNorm normalized name: Precedex 200 MCG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received dexmedetomidine (1.5 μg/kg) as single injection over 10 minutes.
Trial: NCT04741477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a placebo product (without cannabinoids) will be topically applied
Trial: NCT05236998
Drug: SID1903 (FDC)
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of SID1903 (FDC) after an overnight fast
Trial: NCT05549115
Drug: clarithromycin-sensitive(first-line)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
Trial: NCT05549115
Drug: clarithromycin-resistant(first-line)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days
Trial: NCT05549115
Drug: empirical therapy group first-line
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days
Trial: NCT06374901
Drug: SOX/XELOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative treatment with SOX/XELOX
Trial: NCT04754451
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attach two lidocaine patches for 12 hours, one above and below the incision site.
Trial: NCT05664919
Drug: SA58 Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
Trial: NCT06244758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is administered orally.
Trial: NCT05868200
Drug: Capitano zenzero toothpaste
RxNorm normalized name: Lespedeza capitata flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filming toothpate formulation, enriched with 3%ginger as active ingredient and Zinc coco sulfate as surfactant, cleansing and emulsifying agent.~Subjectswill then be given the test intervention, Capitano zenzero toothpaste, and will be asked to brush with it for two minute twice per day and will be instructed torefrain from eating and drinking for 30 min after brushing. participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
Trial: NCT05868200
Drug: Colgate total toothpaste
RxNorm normalized name: Colgate Total Toothpaste Whitening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will then be given Colgate total toothpaste, as an active comparator, and will be asked to brush with it for two minutes twice per day and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles . participants will be received a toothbrush with medium-hardness bristles .the bass technique method of brushing by was comprehensively explained to all participants.. Next, the participants will be re-evaluated after 3 months .
Trial: NCT04732182
Drug: Standard of Care medication for early Alzheimer's Disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease
Trial: NCT00005112
Drug: Human recombinant growth hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05452785
Drug: DFD-29 (Minocycline) Fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each study period, a single 40 mg dose of DFD-29 Capsules will be administered orally with approximately 240 mL of water, in the morning, following a 10-hour overnight fast and 30 minutes after the start of a high-fat, high-calorie breakfast.
Trial: NCT05283850
Drug: High Calcium, Low Sodium (HCLS) Crystalloid Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-normal saline IV drip and 1g IV bolus Calcium Chloride.
Trial: NCT05283850
Drug: High Calcium, High Sodium (HCHS) Crystalloid Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline IV drip and 1g IV bolus Calcium Chloride.
Trial: NCT05067270
Drug: Humalog diluent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC infusion.
Trial: NCT05522439
Drug: SHR-1703 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered by the SC route.
Trial: NCT04453293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaccine diluent, 0.1 mL given as single dose by intradermal injection over the outer lower aspect of the deltoid region
Trial: NCT05970016
Drug: TCC1727 tablet（1）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCC1727 tablet will be administered orally once a day (QD) every morning for 3 days followed by discontinuation for 4 days, and 21 days/cycle on an empty stomach.
Trial: NCT05970016
Drug: TCC1727 tablet（2）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: TCC1727 tablet TCC1727 tablet will be administered orally twice a day (BID) every morning , and 21 days/cycle on an empty stomach.
Trial: NCT06330038
Drug: Inhaled anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anesthetics will be used for the maintenance of general anesthesia.
Trial: NCT06561672
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous injection of 1.5 microgram/kg fentanyl will be given to the patient followed by induction agents (propofol 2mg/kg).
Trial: NCT05275907
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg capsule once daily for 6 weeks
Trial: NCT05361772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 0.5mg per day for 24 months
Trial: NCT06154837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT06653322
Drug: HR-1703
RxNorm normalized name: Synovex H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR-1703 will be administered by SC injection.
Trial: NCT06653322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered by the SC injection.
Trial: NCT06488924
Drug: JR-446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05573204
Drug: Obeticholic Acid Oral Tablet
RxNorm normalized name: obeticholic acid Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obeticholic acid used as 10 mg tablet once daily for 6 months
Trial: NCT04629339
Drug: INCB086550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB086550 will be administered orally twice a day.
Trial: NCT03999216
Drug: Loop Diuretics vs. loop + thiazide diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
Trial: NCT04788979
Drug: Melatonin 5Mg Oral Tablet
RxNorm normalized name: Melatonin 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. control without treatment~2. obese periodontitis patients treated only by scaling and root planning~3. obese periodontitis patients treated with scaling and root planning with daily dietary supplementation of 5 mg melatonin (NOW-USA)
Trial: NCT05195008
Drug: BIIB113-Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05195008
Drug: 11^C]BIO-1819578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT06110130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take Placebo 10 mg orally daily for 4 months
Trial: NCT04951986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical to Prednisone
Trial: NCT06151561
Drug: AGN-151586
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT06151561
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injection
Trial: NCT05698680
Drug: Prednisolone 30 mg Tablet
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See treatment arm Prednisolone
Trial: NCT05493735
Drug: Placebo Jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the control arm will undergo pessary removal and reinsertion after the application of lubricating jelly.
Trial: NCT06301880
Drug: The topical application of a vasodilator on the LIMA graft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were randomly assigned to receive the topical application of one of three agents: milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline, or normal saline (0.9% sodium chloride solution) as control.
Trial: NCT06302218
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: only spinal anesthesia
Trial: NCT05564169
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment per os
Trial: NCT05564169
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine
Trial: NCT05947383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 100 mg oral capsule
Trial: NCT06561763
Drug: Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2， Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14； Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total
Trial: NCT06561594
Drug: recombinant human follicle-stimulating hormone-CTP Fusion protein injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IF Weight \> 60kg，150ug, H. Administer the drug once every 14 days for 64 weeks；IF Weight \>≤60kg，100ug, H. Administer the drug once every 14 days for 64 weeks
Trial: NCT06561594
Drug: recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml, H. Administer the drug once every 14 days for 64 weeks
Trial: NCT05156827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered through IV infusion over an hour